Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

[1]  J. Dipersio,et al.  Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  G. Tripepi,et al.  Plerixafor on‐demand combined with chemotherapy and granulocyte colony‐stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs , 2014, British Journal of Haematology.

[3]  J. Pérez-Simón,et al.  Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors , 2013, Transfusion.

[4]  G. Zararsiz,et al.  The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  R. Vogel,et al.  Improved survival over the last decade in pediatric patients requiring dialysis after hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  A. Nademanee,et al.  Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  C. Flowers,et al.  Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  H. Prince,et al.  Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells , 2013, Bone Marrow Transplantation.

[9]  M. Freund,et al.  Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors , 2013, Bone Marrow Transplantation.

[10]  R. Stuart,et al.  Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis , 2012, Transfusion.

[11]  M. Möttönen,et al.  The use of plerixafor in harvesting autologous stem cells in the pediatric setting , 2012, Pediatric blood & cancer.

[12]  F. Awan,et al.  Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  W. Wiktor-Jedrzejczak,et al.  Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF , 2012, Bone Marrow Transplantation.

[14]  T. Geiger,et al.  Prediction of CD34(+) cell yield in hematopoietic cell products from children by peripheral blood CD34(+) cell counts. , 2012, Cytotherapy.

[15]  G. Dini,et al.  Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. , 2012, Blood.

[16]  N. Kröger,et al.  Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  L. Rybicki,et al.  Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia , 2012, Bone Marrow Transplantation.

[18]  E. Jantunen,et al.  Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: Implications for pre-emptive plerixafor use , 2012, Annals of Hematology.

[19]  D. Dingli,et al.  Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma , 2012, American journal of hematology.

[20]  R. Luksch,et al.  A Phase II study on the safety and efficacy of a single dose of pegfilgrastim for mobilization and transplantation of autologous hematopoietic stem cells in pediatric oncohematology patients , 2011, Transfusion.

[21]  C. Flowers,et al.  Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics , 2011, Transfusion.

[22]  D. Niederwieser,et al.  The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation , 2011, Bone Marrow Transplantation.

[23]  A. Nademanee,et al.  Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  Yu-Hong Chen,et al.  The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA‐mismatched/haploidentical hematopoietic stem cell transplantation , 2011, Pediatric blood & cancer.

[25]  F. Foss,et al.  Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. , 2011, Clinical lymphoma, myeloma & leukemia.

[26]  E. Jantunen,et al.  Efficacy of pre‐emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience , 2011, European journal of haematology.

[27]  D. Hren,et al.  Large volume leukapheresis: Efficacy and safety of processing patient's total blood volume six times. , 2011, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[28]  C. Elie,et al.  First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor , 2011, Advances in therapy.

[29]  W. Wood,et al.  Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  N. Russell,et al.  Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data , 2011, Bone Marrow Transplantation.

[31]  Martinelli Giovanni,et al.  A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[32]  Monika Mielcarek,et al.  Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  V. Semiglazov,et al.  A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer , 2010, Oncology Research and Treatment.

[34]  E. Gordon-Smith,et al.  Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia , 2010, Bone Marrow Transplantation.

[35]  S. Ansell,et al.  CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies , 2010, Bone Marrow Transplantation.

[36]  C. Urban,et al.  Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies , 2010, Pediatric blood & cancer.

[37]  Yu-Hong Chen,et al.  The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation , 2009, Pediatric blood & cancer.

[38]  M. Gertz,et al.  Clinical Impact and Resource Utilization After Stem Cell Mobilization Failure in Patients with Multiple Myeloma and Lymphoma. , 2009 .

[39]  S. Steinberg,et al.  Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas , 2009, Clinical Cancer Research.

[40]  G. Ehninger,et al.  Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. , 2009, Blood.

[41]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Klein,et al.  Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. , 2009, Blood.

[43]  Dae-Ho Lee,et al.  Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non‐Hodgkin's lymphoma , 2009, Transfusion.

[44]  A. Nademanee,et al.  Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[46]  U. Popat,et al.  Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma , 2009, American journal of hematology.

[47]  Michael L. Wang,et al.  Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  J. Klein,et al.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. , 2009, Blood.

[49]  F. Callera,et al.  Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. , 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[50]  Á. Lassaletta,et al.  Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile , 2009, British journal of haematology.

[51]  L. Gordon,et al.  Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation , 2009, Leukemia & lymphoma.

[52]  A. Giglio,et al.  XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy , 2009, Leukemia & lymphoma.

[53]  Y. Lee,et al.  Mobilization effects of G‐CSF, GM‐CSF, and darbepoetin‐α for allogeneic peripheral blood stem cell transplantation , 2009, Journal of clinical apheresis.

[54]  A. Minguela,et al.  Large‐volume‐apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients , 2009, Journal of clinical apheresis.

[55]  Tso-fu Wang,et al.  Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[56]  R. Vij,et al.  Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[57]  R. Vij,et al.  Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. , 2008, Blood.

[58]  J. Leonard,et al.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[59]  David D. Smith,et al.  Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  N. Schmitz,et al.  A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy , 2008, Haematologica.

[61]  G. Tricot,et al.  AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data , 2008, Bone Marrow Transplantation.

[62]  T. Çalikoglu,et al.  Medulloblastoma/primitive neuroectodermal tumor in adults: prognostic factors and treatment results: a single-center experience from Turkey , 2008, Medical oncology.

[63]  L. Rybicki,et al.  Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies , 2007, Bone Marrow Transplantation.

[64]  K. Chiang,et al.  Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony‐stimulating factor‐primed bone marrow and steady‐state bone marrow , 2007, Pediatric transplantation.

[65]  S. Mackinnon,et al.  Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony‐stimulating factor (G‐CSF): impact of age, sex, donor weight and type of G‐CSF used , 2006, British journal of haematology.

[66]  M. Labopin,et al.  Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Wiley Interscience,et al.  The number of CD34+ cells in peripheral blood as a predictor of the CD34+ yield in patients going to autologous stem cell transplantation , 2006, Journal of clinical apheresis.

[68]  J. Szer,et al.  Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[69]  Y. Wakata,et al.  Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor , 2006, Bone Marrow Transplantation.

[70]  Y. Kilic,et al.  Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. , 2006, Haematologica.

[71]  J. Wingard,et al.  The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[72]  J. Huh,et al.  Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma , 2005, Annals of Hematology.

[73]  A. Seber,et al.  Large-volume leukapheresis for peripheral blood progenitor cell collection in low body weight pediatric patients: a single center experience. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[74]  Z. Gašová,et al.  PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[75]  S. Grupp,et al.  Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003 , 2005, Bone Marrow Transplantation.

[76]  M. Baccarani,et al.  Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. , 2005, Haematologica.

[77]  G. Ehninger,et al.  Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. , 2005, Haematologica.

[78]  D. Margolis,et al.  Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. , 2004, Journal of pediatric hematology/oncology.

[79]  D. Serrano,et al.  A randomised study of 10 μg/kg/day (single dose) vs 2 × 5 μg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients , 2003, Bone Marrow Transplantation.

[80]  J. Miguel,et al.  Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. , 2003, Blood.

[81]  J. Bourhis,et al.  Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation , 2003, Leukemia.

[82]  D. Orbach,et al.  Peripheral blood stem cell collection in 24 low-weight infants: experience of a single centre , 2003, Bone Marrow Transplantation.

[83]  M. Beyzadeoğlu,et al.  Stem cell mobilization by G‐CSF in solid and hematological malignancies: Single daily dose is better than split dose in obese patients , 2003, Journal of clinical apheresis.

[84]  F. Buadi,et al.  Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis , 2003, Bone Marrow Transplantation.

[85]  A. Verdeguer,et al.  Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. , 2003, Haematologica.

[86]  F. Garcia-sanchez,et al.  Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients , 2002, Bone Marrow Transplantation.

[87]  J. Suh,et al.  GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation , 2002, Bone Marrow Transplantation.

[88]  N. Kröger,et al.  Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors , 2002, Bone Marrow Transplantation.

[89]  N. Kröger,et al.  Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. , 2002, Bone marrow transplantation.

[90]  S. Heimfeld,et al.  CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. , 2001, Blood.

[91]  G. Ehninger,et al.  Spleen enlargement in healthy donors during G–CSF mobilization of PBPCs , 2001, Transfusion.

[92]  W. Krüger,et al.  A randomized comparison of once versus twice daily recombinant human granulocyte colony‐stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation , 2000, British journal of haematology.

[93]  K. Schulman,et al.  Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  J. Klassen,et al.  Image‐guided central venous catheter placement for apheresis in allogeneic stem cell donors , 2000, Journal of clinical apheresis.

[95]  Y. Shima,et al.  in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels , 2000 .

[96]  E. Ito,et al.  Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. , 1999, Cancer research.

[97]  C. Waller,et al.  High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  P. Anderlini,et al.  Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience , 1999, Transfusion.

[99]  W. Leisenring,et al.  The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield , 1999, Transfusion.

[100]  M. Sugrue,et al.  Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight , 1999, Bone Marrow Transplantation.

[101]  O. Haas,et al.  G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability , 1999, Annals of Hematology.

[102]  F. Aversa,et al.  Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor , 1999, The Lancet.

[103]  F. Garcia-sanchez,et al.  Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. , 1999, Haematologica.

[104]  R. Clark,et al.  Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system , 1998, Bone Marrow Transplantation.

[105]  G. Salles,et al.  High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation , 1998 .

[106]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[107]  J. Miguel,et al.  Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation , 1998, Transfusion.

[108]  G. Salles,et al.  High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. , 1998, Blood.

[109]  W. Velasquez,et al.  Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy , 1997, Bone Marrow Transplantation.

[110]  R. Hargreaves,et al.  When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[112]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[113]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[114]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Y. Kawano,et al.  Collection and transplantation of peripheral blood stem cells in very small children weighting 20 kg or less. , 1995, Blood.

[116]  L. Terstappen,et al.  Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.

[117]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.